U.S. FDA grants priority review to Boehringer Ingelheim’s Afatinib* NDA for EGFR mutation-positive advanced NSCLC
16 January 2013 | By Boehringer Ingelheim
The acceptance of the NDA filing reinforces our ongoing commitment to oncology..."
List view / Grid view
16 January 2013 | By Boehringer Ingelheim
The acceptance of the NDA filing reinforces our ongoing commitment to oncology..."
7 January 2013 | By Boehringer Ingelheim
Top-line results for four completed Phase III clinical trials...
7 January 2013 | By Boehringer Ingelheim
Announces it will begin remainder of pre-planned clinical trials for LY2605541...
11 December 2012 | By Boehringer Ingelheim
Boehringer Ingelheim’s Metacam® has obtained EU wide marketing authorizations...
10 December 2012 | By Boehringer Ingelheim
Results from a new post-hoc analysis...
10 December 2012 | By Boehringer Ingelheim
New positive Phase II results...
5 December 2012 | By Boehringer Ingelheim
"We are very pleased to partner with Apexigen..."
14 November 2012 | By Boehringer Ingelheim
Today sees the culmination of weeklong activities at Boehringer Ingelheim...
13 November 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and BaroFold, Inc, have entered into a non-exclusive technology and commercial license option agreement...
12 November 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Molecular Partners have entered into a strategic manufacturing collaboration...
10 November 2012 | By Boehringer Ingelheim
Pivotal Phase III interferon-free study being initiated following positive Phase IIb results...
8 November 2012 | By Boehringer Ingelheim
Pivotal data from the RELY-ABLE® study have provided additional data...
8 November 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company are pleased to announce that the recruitment of patients for CAROLINA (Cardiovascular Outcome Study of Linagliptin versus Glimepiride in Patients with Type 2 Diabetes)1 has been completed. Linagliptin is currently the only DPP-4 inhibitor that is being compared to an active comparator in…
5 November 2012 | By Boehringer Ingelheim
New findings presented...
5 November 2012 | By Boehringer Ingelheim
"We welcome the positive conclusions reached..."